BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
Pursuant to the liquidity contract entrusted to TSAF – Tradition Securities by IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext: ALIMP, FR0010458729, PEA-PME eligible), on 30 June 2018 the following assets appeared on the liquidity account:
- Number of shares: 160,000
- Cash balance of the liquidity account: €34,349.25
As a reminder, at the time of the last half-yearly report on 31 December 2017, the following resources were booked to the liquidity account:
- Number of shares: 156,000
- Cash balance of the liquidity account: €35,509.25
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80